SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1732Depend how serious are they, and how often they develop. Rate does not support bMiljenko Zuanic-3/15/2015
17311.2 vs 0.5 neurocognitive events with praulent vs placebo, is that meaningful?Felix B-3/15/2015
1730finance.yahoo.com The THEORY on neuro-cognitive side effects was based on obserMiljenko Zuanic-3/15/2015
1729[Deleted]DewDiligence_on_SI-2/27/2015
1728No, also listed one did not change # for pts plan.Miljenko Zuanic-2/27/2015
1727I can find only one phase-3 trial listed ( clinicaltrials.gov ). Is there anotheDewDiligence_on_SI-2/27/2015
17261700 pts is for PIII program (two PIII trials). They did introduce 3 and 6 mg doMiljenko Zuanic-2/27/2015
1725Not in the PR. The data may be available through The Macula Society, but I didn&DewDiligence_on_SI-2/27/2015
1724No details? novartis.comMiljenko Zuanic-2/27/2015
1723Point is...????...FOMiljenko Zuanic-2/24/2015
1722Olivier Brandicourt, the new CEO at SNY, should be very good for the collaboratiBiotech Jim-2/20/2015
1721Results are "Not bad"! Interesting that Bayer DME POLARIS trial is stMiljenko Zuanic-2/19/2015
1720NIH Comparative Effectiveness Study in Diabetic Macular Edema published in the NBiotech Jim12/19/2015
1719Impressive DD, was not aware there was that much competition!Felix B-2/17/2015
1718As summer approach, debate will heat up! Well, it will be warmer weather, anywayMiljenko Zuanic-2/17/2015
1717So, what are chances for Regeneron to obtain "breakthrough treatment designMiljenko Zuanic-2/13/2015
1716This Novartis Ab-combination (IL-4 and IL-13) may be direct competition, but whyMiljenko Zuanic-2/13/2015
1715AZN Tralokinumab (Ab against IL-13) PIIb results: atsjournals.orgMiljenko Zuanic-2/13/2015
1714AZN Benralizumab (Ab against IL-5R) PIIb results: thelancet.comMiljenko Zuanic-2/13/2015
1713GSK Mepolizumab (Ab against IL-5), PIII results: nejm.orgMiljenko Zuanic-2/13/2015
1712Teva Reslizumab (Ab against IL-5, IV-route), PIII results: tevapharm.comMiljenko Zuanic-2/13/2015
1711Roche Labrikizumab (Ab to IL-13) trial results for asthma: nejm.orgMiljenko Zuanic-2/13/2015
1710Single PIII trial for severe asthma, "breakthrough designation" is posMiljenko Zuanic-2/10/2015
1709REGN Q and 2014 earnings... files.shareholder.com - "Fourth quarter 2014Biotech Jim-2/10/2015
1708Thanks, saw that. NVS seams confident, and it may be small incremental improvemeMiljenko Zuanic-1/30/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News